NEW YORK, July 24, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Synergy Pharmaceuticals Inc. (NASDAQ: SGYP),
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Orexigen
Therapeutics Inc. (NASDAQ: OREX), Prana Biotechnology Ltd (NASDAQ:
PRAN), and Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP). Free
research report on Synergy Pharma can be accessed at
https://www.EquityResearchInstitute.com/reports?keyword=SYGP On
Thursday, July 23, 2015, the NASDAQ
Composite ended at 5,146.41, down 0.49%, the Dow Jones Industrial
Average declined 0.67%, to finish the day at 17,731.92, and the
S&P 500 closed at 2,102.15, down 0.57%. The losses were broad
based as eight out of nine sectors ended the session in negative.
Register for your complimentary reports at the links given below.
Synergy Pharmaceuticals Inc.'s stock finished Thursday's session
1.64% lower at $8.42. A total of 3.41
million shares were traded, which was below its three months
average volume of 5.52 million shares. Over the last one month and
the previous three months, Synergy Pharmaceuticals Inc.'s shares
have surged 3.69% and 104.87%, respectively. Additionally, the
stock has rallied 176.07% since the beginning of 2015. The
company's shares are trading above their 50-day and 200-day moving
averages by 28.09% and 105.26%, respectively. Synergy
Pharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of
53.19. Sign up and read the free notes on SYGP at:
https://www.EquityResearchInstitute.com/reports?keyword=SGYP
On Thursday, shares in Teva Pharmaceutical Industries Ltd ended
the session flat at $62.51. The stock
reported a trading volume of 1.53 million shares, below its three
months average volume of 3.87 million shares. Shares of the company
traded at a PE ratio of 19.47. Although, Teva Pharmaceutical
Industries Ltd's shares have lost 0.62% in the previous three
months, it has advanced 4.53% in the last one month and 9.96% on
YTD basis. The stock is trading 2.47% above its 50-day moving
average and 6.99% above its 200-day moving average. Moreover,
shares of Teva Pharmaceutical Industries Ltd have an RSI of 55.18.
The complimentary notes on TEVA can be downloaded in PDF format
at:
https://www.EquityResearchInstitute.com/reports?keyword=TEVA
Orexigen Therapeutics Inc.'s stock declined 4.02%, to close the
day at $3.82. The stock recorded a
trading volume of 4.85 million shares, much above its three months
average volume of 2.54 million shares. Over the last one month and
over the past three months, Orexigen Therapeutics Inc.'s shares
have declined 22.98% and 48.66%, respectively. Furthermore, the
stock has plummeted 36.96% since the start of this year. The
company's shares are trading 20.28% below their 50-day moving
average and 32.58% below their 200-day moving average.
Additionally, Orexigen Therapeutics Inc. has an RSI of 25.55.
Register for free on Equity Research Institute and access the
latest research on OREX at:
https://www.EquityResearchInstitute.com/reports?keyword=OREX
On Thursday, shares in Prana Biotechnology Ltd recorded a
trading volume of 0.09 million shares, lower than their three
months average volume of 0.53 million shares. The stock ended the
day 2.56% higher at $1.20. Although,
Prana Biotechnology Ltd's stock has advanced 7.14% in the past
three months, it has declined 9.09% in the last one month and
26.83% on YTD basis. The company is trading below its 50-day and
200-day moving averages by 6.34% and 16.30%, respectively.
Furthermore, shares of Prana Biotechnology Ltd have an RSI of
48.37. The complete research on PRAN is available for free at:
https://www.EquityResearchInstitute.com/reports?keyword=PRAN
Sucampo Pharmaceuticals Inc.'s stock lost 5.77%, to close
Thursday's session at $19.60. The
stock recorded a trading volume of 0.78 million shares, above its
three months average volume of 0.54 million shares. Over the last
one month and since the start of this year, Sucampo Pharmaceuticals
Inc.'s shares have surged 14.55% and 37.25%, respectively. However,
the stock has lost 8.41% in the previous three months. The company
is trading 15.55% and 31.74% above its 50-day and 200-day moving
averages, respectively. Furthermore, Sucampo Pharmaceuticals Inc.'s
stock traded at a PE ratio of 47.80 and has an RSI of 57.59. Free
in-depth research on SCMP is available at:
https://www.EquityResearchInstitute.com/reports?keyword=SCMP
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"),
provides necessary guidance in preparing the document templates.
The Reviewer has reviewed and revised the content, as necessary,
based on sound investment judgment and publicly available
information which is believed to be reliable. The Reviewer and the
CFA® have not performed any independent investigations or forensic
audits to validate the information herein. Unless otherwise noted,
any content outside of this document has no association with the
Author, the Reviewer, or the CFA® (collectively referred to as the
"Production Team") in any way. The Production Team is compensated
on a fixed monthly basis and do not hold any positions of interest
in any of the securities mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the CFA® (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.equityresearchinstitute.com.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia. Do not send email to
robottrap (at) equityresearchinstitute.com.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.equityresearchinstitute.com
